Saturday 17 October 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
28.82
0.28
−0.96%
Follow ARQT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 119.18 |
P/S ratio |
7.57 | 9.82 | 7.33 | 7.38 | |
P/FCF ratio |
0.00 | 0.00 | 269.53 | 142.16 | |
P/Operating CF |
(1,371.55) | 141.11 | 1,361.25 | 270.77 | |
P/B ratio |
15.22 | 19.50 | 16.07 | 15.52 | |
Price to Tangible BV |
16.86 | 21.15 | 17.38 | 16.54 | |
EV/Sales |
7.31 | 9.53 | 7.06 | 7.10 | |
EV/EBITDA |
0.00 | 0.00 | 724.90 | 92.59 | |
EV/Operating CF |
(71.34) | (636.90) | 108.65 | 83.76 | |
EV/FCF |
(48.15) | (168.11) | 259.37 | 136.76 | |
Quick Ratio |
3.07 | 2.83 | 2.26 | 2.46 | |
Current Ratio |
3.50 | 3.17 | 2.68 | 2.92 | |
Net Debt/EBITDA |
(9.71) | (5.92) | 13.19 | (7.75) | |
Debt/Assets |
29.25% | 25.17% | 23.79% | 22.29% | |
Debt/Equity |
0.69 | 0.58 | 0.58 | 0.49 | |
Asset Turnover |
0.79 | 0.96 | 1.03 | 1.10 | |
Operating CF/Net income |
(0.24) | 1.51 | (0.20) | 0.84 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.46) | |
Interest Coverage |
2.78 | 6.13 | (2.08) | 4.82 | |
Research and Development Expense of Revenue |
19.76% | 15.79% | 29.06% | 15.67% | |
Selling, General and Administrative Expense of Revenue |
62.90% | 60.98% | 70.28% | 63.25% | |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
10.12% | 7.77% | 10.14% | 9.83% | |
Graham Net Nets |
0.06 | 0.05 | 0.06 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 2.89 | |
Earnings Yield |
(1.91%) | (0.45%) | (0.08%) | 0.84% | |
Free Cash Flow Yield |
(2.01%) | (0.58%) | 0.37% | 0.70% | |
Revenue per Share |
0.78 | 1.02 | 0.81 | 0.99 | |
Operating CF per Share |
(0.01) | 0.21 | 0.02 | 0.10 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | 0.21 | 0.02 | 0.10 | |
Cash per Share |
1.50 | 1.74 | 1.73 | 1.83 | |
Shareholders Equity per Share |
1.24 | 1.49 | 1.47 | 1.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.24 | 1.49 | 1.47 | 1.69 | |
Free Cash Flow |
(1.75) | 26.19 | 2.24 | 12.48 | |
Working Capital |
249.45 | 281.39 | 274.85 | 307.33 | |
Capital Expenditures |
0.00 | 0.00 | — | (0.16) | |
Net Current Asset Value |
136.32 | 167.74 | 167.70 | 199.71 | |
EV/EBIT |
0.00 | 0.00 | 912.84 | 96.12 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 948.60 | 99.91 | |
| Other line items | |||||
Average Receivables |
87.62 | 109.65 | 114.90 | 130.93 | |
Average Payables |
12.56 | 13.37 | 21.41 | 10.84 | |
Average Inventory |
18.22 | 18.58 | 27.00 | 27.60 | |
Average Assets |
404.17 | 390.93 | 402.05 | 420.49 | |
Average Common Equity |
157.36 | 173.51 | 166.15 | 179.78 |
Columns are period end dates